Biotechnology

Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology

April 14, 2021 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) On April 7, 2021 Oncology Pharma, Inc. (the "Company") reported that it had been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize pancreatic cancer treatments utilizing Regen's proprietary intellectual property pertaining to mRNA. A Spokesperson for the Company, today expanded on the reasons for obtaining this...

Read more

Pressure BioSciences Finalizes Plan to Acquire Global Eco-Friendly Agrochemical Supplier

April 14, 2021 7:31 AM

Company Expects Acquisition to be Accretive with Sustained Profitable Revenue Growth, Leveraging Market-Changing Synergy from PBI's Ultra Shear Technology Nanoemulsions Platform SOUTH EASTON, MA / ACCESSWIRE / April 14, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide...

Read more

Enveric Biosciences to Participate in the Planet MicroCap Showcase on April 21st

April 14, 2021 7:30 AM

NAPLES, FL / ACCESSWIRE / April 14, 2021 / Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David Johnson, Chairman and Chief Executive Officer, will present at the Planet MicroCap Showcase to be held virtually on Wednesday, April 21, 2021 at 9:00 a.m. ET. To access the live...

Read more

Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network

April 14, 2021 7:00 AM

DehydraTECHTM Powers Amari's Award-Winning Products KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced that its corporate client Amari Corp.'s "Everyday Calm" CBD product was named a Top CBD Product Pick by New Hope Network, host of the industry-leading Natural Products Expo conference events....

Read more

Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada

April 14, 2021 2:00 AM

REDUVO would have Canada's only Drug Identification Number for a THC-based prescription drug The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / April 14, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have advanced the REDUVO soft gel capsules New Drug Submission (NDS)...

Read more

Viewpoint Molecular Targeting(TM) Presents Positive Preclinical Results of VMT01 at the 2021 American Association for Cancer (AACR) Annual Meeting

April 13, 2021 10:00 AM

- Preclinical study evaluated melanocortin 1 receptor (MC1R) as a potential target for MC1R-targeted therapies for metastatic melanoma, the lead target of VMT01 - - Results indicate that MC1R-targeted therapies, such as VMT01, are a promising alternative to current therapies for metastatic melanoma - - Company is launching Phase 1 imaging study of VMT01 imminently with provisional results expected in Q4 2021, followed by Phase 1/2a therapy...

Read more

Philogen Announces Publication of Best-in-Class FAP-Targeting Small Molecule Ligand (OncoFAP) in PNAS

April 12, 2021 3:00 PM

(i) Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs - (ii) OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer SIENA, ITALY / ACCESSWIRE / April 12, 2021 / Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to...

Read more

Protean BioDiagnostics Presents Poster at AACR 2021 Annual Meeting

April 12, 2021 10:00 AM

Innovative OncoSignal technology enables rapid measurement of key oncogenic signaling pathways for targeted breast cancer treatment ORLANDO, FL / ACCESSWIRE / April 12, 2021 / Protean BioDiagnostics Inc. ("Protean"), a disruptive biotechnology company developing and commercializing novel cancer diagnostics supporting precision oncology, today announced that Dr. Anthony Magliocco, President and CEO of Protean, presented a poster at the...

Read more

Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry

April 12, 2021 8:45 AM

(i) Study shows the generation of a high-quality stereo- and regiodefined DNA-encoded chemical library - (ii) Identified ligands against tumor-associated antigens can serve as vehicles for pharmacodelivery applications SIENA, ITALY / ACCESSWIRE / April 12, 2021 / Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, is...

Read more

Philogen Announces Participation to the 10th World Congress of Melanoma

April 12, 2021 8:45 AM

(i) Philogen will give a poster presentation about the phase II study of Daromun (Nidlegy) for the treatment of non-melanoma skin cancer - (ii) Study shows promising early signs of efficacy in patients with basal cell carcinoma SIENA, ITALY / ACCESSWIRE / April 12, 2021 / Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule...

Read more

Applied UV Receives Patent for Pathogen Destroying Devices in China

April 12, 2021 8:30 AM

Adds to Company's Portfolio of Patents for Disinfection Technology Addressing Global Challenge of Controlling the Spread of Emerging Pathogens MOUNT VERNON, NY / ACCESSWIRE / April 12, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to...

Read more

ANGLE's Parsortix system showcased at AACR 2021

April 12, 2021 2:00 AM

ANGLE'S PARSORTIX SYSTEM SHOWCASED IN POSTER PRESENTATIONS AT LEADING CANCER CONFERENCE Publication of study results demonstrating the capabilities of two new assays in clinical samples at AACR 2021 Immunotherapy assay enables determination of PD-L1 status in significant proportion of patients and could guide personalised treatment selection GUILDFORD, SURREY / ACCESSWIRE / April 12, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a...

Read more

Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting

April 10, 2021 2:15 PM

Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa Durable anti-tumor activity in heavily pre-treated patient population ​including "cold" and HER2-low expressing tumors Dose-dependent immune activation and 4-1BB modulation in both HER2-high and HER2-low expressing patients PRS-344/S095012 preclinical data show that the...

Read more

Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR

April 10, 2021 8:30 AM

Data support potential of DARPin® CD3 T-cell engager candidate for improved safety window while limiting tumor escape New data show that the FAP x CD40 product candidate, MP0317, led to a localized macrophage repolarization and reversion of T-cell suppression. Clinical trials expected to initiate in the second half of 2021 Effector control technologies give new potential for enhancing current and future immunotherapies while reducing...

Read more

Helix BioPharma Corp. Extends Period to Exercise Warrants

April 9, 2021 5:00 PM

RICHMOND HILL, ON / ACCESSWIRE / April 9, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend the exercise period of a total of 2,837,000 outstanding common share purchase warrants (the "Warrants"), all...

Read more

Wuhan General Group Introduces Liviana(TM) CBD Infused Artisanal Olive Oil

April 9, 2021 11:25 AM

CAPE TOWN, SA / ACCESSWIRE / April 9, 2021 / WUHAN GENERAL GROUP, INC. (OTC:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update regarding its latest brand offering: We are thrilled to introduce our upcoming brand LivianaTM which is set to launch in May 2021. The LivianaTM brand will kick off its product line with a...

Read more

EV Biologics Confirms Funding to Commence Cell Line Generation & Advance Exosome Research

April 8, 2021 9:30 AM

NASHVILLE, TN / ACCESSWIRE / April 8, 2021 / EV Biologics Corp (OTC PINK:YECO) today announced that it has signed a director's loan agreement to secure funding of up to $5 million to start generation of a novel exosome-producer cell line and production of therapeutic exosomes for preclinical research. The Company has finalized its preparation and is ready to begin generation of a novel exosome-producer master cell bank to enable manufacturing...

Read more

Havn Life Completes Acquisition of Strategic Manufacturing & Packaging Facility for its Retail Division

April 8, 2021 8:00 AM

The Facility acquisition positions Havn Life to quickly expand its product portfolio and reach additional NHP categories. VANCOUVER, BC / ACCESSWIRE / April 8, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce, further to its news release...

Read more

Integrated BioPharma Announces Launch of Investors Website

April 8, 2021 8:00 AM

Integrated BioPharma Announces Launch of Investors Website HILLSIDE, NJ / ACCESSWIRE / April 8, 2021 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") announces the launch of an updated investors website. "As part of our efforts in supporting Integrated BioPharma, Inc. and its shareholders in the public markets, we are excited to announce, that effective today, INBP has launched an updated Investors Website providing...

Read more

Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer

April 7, 2021 3:30 PM

SAN FRANCISCO, CA / ACCESSWIRE / April 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) signed a license agreement with Regen BioPharma Inc. for intellectual property pertaining to mRNA to be used in developing a therapy for treating pancreatic cancer. This license agreement expands the Company's portfolio of intellectual property that It plans to develop for niche biotechnology markets. Oncology Pharma issued a statement "We are looking to...

Read more